The New Alzheimer’s Diagnostic Architecture: Where Does pTau217 Fit?

Event Notes:

The clinical landscape for diagnosing and treating Alzheimer’s disease is shifting rapidly. As disease-modifying therapies continue to be part of the clinical conversation, the need for highly accurate, scalable and accessible diagnostic approaches is becoming increasingly important.

But what could this mean for the way patients are assessed and diagnosed in everyday practice? Join Roche and the British Neuroscience Association (BNA) for an expert-led webinar exploring the potential of blood-based biomarkers to redefine the Alzheimer’s diagnostic pathway. We’ll spotlight plasma pTau217, including emerging clinical use cases and how it could potentially support decision making across the patient journey.

This is a partnered event with organisational members, Roche.